(Q39708963)

English

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

Mohammad Ali

9

0 references

11

object named as

Firdausi Qadri

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

8

object named as

John Clemens

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Fahima Chowdhury

5

object named as

Fahima Chowdhury

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Md Saruar Bhuiyan

4

object named as

Md Saruar Bhuiyan

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

3

object named as

Farhana Khanam

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Ashraful Islam Khan

6

object named as

Ashraful Islam Khan

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Mohiul Islam Chowdhury

2

object named as

Mohiul Islam Chowdhury

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Iqbal Ansary Khan

7

object named as

Iqbal Ansary Khan

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

author name string

Amit Saha

1

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Alejandro Cravioto

10

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

language of work or name

0 references

publication date

9 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

46

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

8285-8292

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

The origin of the Haitian cholera outbreak strain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The case for reactive mass oral cholera vaccinations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Endemic cholera in rural Bangladesh, 1966-1980.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18–36 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Field trial of a locally produced, killed, oral cholera vaccine in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.108

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.08.108

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39708963&oldid=2089065862"